



# Provisional Funding Algorithm

Indication: Non-small cell lung cancer without  
actionable oncogenic alterations



**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the *Canadian Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

### Background

Following a request from jurisdictions, CADTH may design or update an algorithm depicting the sequence of funded treatments for a particular tumour type. These algorithms are proposals for the jurisdictions to implement and adapt to the local context. As such, they are termed “provisional.” Publishing of provisional algorithms is meant to improve transparency of the oncology drug funding process and promote consistency across jurisdictions.

Provisional funding algorithms are based on 3 principal sources of information:

- CADTH pCODR Expert Review Committee (pERC) reimbursement recommendations and/or implementation guidance regarding drug place in therapy and sequencing.
- implementation advice from panels of clinicians convened by CADTH concerning sequencing of drugs in the therapeutic space of interest.
- existing oncology drug reimbursement criteria and legacy funding algorithms adopted by jurisdictional drug plans and cancer agencies.

Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management of each patient nor the provision of each drug regimen. The diagrams may not contain a comprehensive list of all available treatments, and some drugs may not be funded in certain jurisdictions. All drugs are subject to explicit funding criteria, which may also vary between jurisdictions. Readers are invited to refer to the cited sources of information on the CADTH website for more details.

Provisional funding algorithms also delineate treatment sequences available to patients who were never treated for the condition of interest (i.e., incident population). Time-limited funding of new options for previously or currently treated patients (i.e., prevalent population) is not detailed in the algorithm.

Provisional funding algorithms may contain drugs that are under consideration for funding. Algorithms will not be dynamically updated by CADTH following changes to drug funding status. Revisions and updates will occur only upon request by jurisdictions.

**Jurisdictional cancer drug programs requested a CADTH provisional funding algorithm on non-small cell lung cancer without actionable oncogenic alterations. However, no outstanding implementation issues were identified, and no additional implementation advice is provided in this report. The algorithm depicted herein is meant to reflect the current and anticipated funding landscape based on the previously mentioned sources of information.**

**Table 1: Relevant CADTH Recommendations**

Generic name (brand name)	Date of recommendation	Recommendation <sup>a</sup> and guidance on treatment sequencing
Cemiplimab (Libtayo)	<a href="#">June 20, 2022</a>	<p>The CADTH pERC recommends that cemiplimab be reimbursed for the first-line treatment of adult patients with NSCLC expressing PD-L1 (programmed death-ligand 1) with a TPS of 50% or greater, as determined by a validated test, with no <i>EGFR</i>, <i>ALK</i>, or <i>ROS1</i> aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC only if the following conditions are met:</p> <ul style="list-style-type: none"> <li>• previously untreated stage IV NSCLC, or stage IIIB or IIIC NSCLC not amenable to curative therapy.</li> <li>• PD-L1 strongly positive tumours (TPS <math>\geq</math> 50%).</li> <li>• good performance status.</li> <li>• patients should not have any of the following:               <ul style="list-style-type: none"> <li>◦ tumours with <i>EGFR</i>, <i>ALK</i>, or <i>ROS1</i> aberrations.</li> <li>◦ a contraindication to immunotherapy.</li> <li>◦ uncontrolled and symptomatic CNS metastases.</li> </ul> </li> </ul> <p><b>Treatment should be:</b></p> <ul style="list-style-type: none"> <li>• renewed for patients who demonstrate a continued response to treatment defined as absence of disease progression, based on clinical and radiographic evaluation every 3 to 4 months.</li> <li>• reimbursed for a maximum of 108 weeks.</li> </ul> <p>Cemiplimab should be negotiated so that it does not exceed the drug program cost of treatment with pembrolizumab.</p> <p><b>Optimal sequencing guidance:</b></p> <ul style="list-style-type: none"> <li>• pERC agreed with the clinical experts and considered that patients who received previous adjuvant or neoadjuvant chemotherapy should be eligible to receive cemiplimab. In addition, patients who progress at least 6 months after their last dose of immunotherapy should be eligible to receive cemiplimab.</li> <li>• pERC noted that the addition of chemotherapy to cemiplimab at disease progression should not be funded as there is insufficient evidence to recommend this practice.</li> <li>• pERC agreed with the clinical experts that patients who completed 2 years of cemiplimab treatment and subsequently progressed and patients who discontinued cemiplimab after less than 2 years due to complete response should be eligible for retreatment for up to 17 cycles (1 year).</li> </ul>
Nivolumab (Opdivo) - Ipilimumab (Yervoy)	<a href="#">March 4, 2021</a>	<p>pERC conditionally recommends the reimbursement of nivolumab plus ipilimumab (nivolumab/ipilimumab) and 2 cycles of PDC, for the first-line treatment of adult patients with metastatic or recurrent NSCLC with no known <i>EGFR</i> or <i>ALK</i> genomic tumour aberrations, if the following condition is met:</p> <ul style="list-style-type: none"> <li>• cost-effectiveness being improved to an acceptable level.</li> </ul> <p>Eligible patients include those with non-squamous or squamous NSCLC, any PD-L1 expression level including patients with unknown PD-L1 expression, and good performance status. Treatment with nivolumab/ipilimumab should continue until</p>

Generic name (brand name)	Date of recommendation	Recommendation <sup>a</sup> and guidance on treatment sequencing
		<p>confirmed disease progression or unacceptable toxicity to a maximum of 2 years, whichever comes first.</p> <p><b>Optimal sequencing guidance:</b></p> <ul style="list-style-type: none"> <li>• pERC agreed with the CGP that patients progressing on nivolumab/ipilimumab would not be eligible for subsequent immunotherapy.</li> <li>• pERC agreed with the CGP that nivolumab/ipilimumab should not be used in combination with non-platinum doublets or single-agent chemotherapy. However, the CGP noted that platinum and gemcitabine have been combined with durvalumab plus tremelimumab in the CCTG IND 226 and BR342 trials. Given there were no safety concerns identified in those trials, pERC agreed with the CGP that jurisdictions may wish to consider allowing the use of platinum and gemcitabine with nivolumab/ipilimumab.</li> <li>• pERC agreed that patients progressing on nivolumab/ipilimumab plus 2 cycles of PDC would be most appropriately treated with chemotherapy as the next treatment option. For patients progressing more than 6 months from completion of PDC, retreatment with a histology-appropriate platinum doublet would be recommended. Patients progressing within 6 months would likely be treated with docetaxel. The CGP noted that retreatment with pemetrexed may pose funding issues in some jurisdictions and this gap should be addressed during implementation. pERC agreed with the CGP that patients with non-squamous NSCLC who have only received 2 cycles of pemetrexed, should have access to the most effective PDC (i.e., platinum plus pemetrexed).</li> <li>• pERC agreed that retreatment with nivolumab/ipilimumab for 1 year be an option for patients progressing after completion of 2 years of nivolumab/ipilimumab.</li> </ul>
Pembrolizumab (Keytruda)	<a href="#">August 23, 2017</a>	<p>pERC recommends reimbursement of pembrolizumab (Keytruda) conditional on the cost-effectiveness being substantially improved to an acceptable level. Funding should be for the treatment of locally advanced or previously untreated metastatic NSCLC in patients whose tumours express PD-L1 (TPS ≥ 50%) as determined by a validated test and who do not harbour a sensitizing EGFR mutation or ALK translocation. Patients with locally advanced disease (stage IIIB) should be eligible for funding if they are not eligible for potentially curative concurrent chemoradiotherapy. Funding should be for patients who have good performance status.</p> <p>Treatment should be administered at a dose of 2 mg/kg up to a total dose amount of 200 mg (dose capped at 200 mg). Treatment should continue until confirmed disease progression or unacceptable toxicity or to a maximum of 2 years (35 cycles), whichever comes first.</p> <p><b>Optimal sequencing guidance:</b></p> <p>In the trial patients could receive retreatment for up to 17 cycles if patients stopped receiving pembrolizumab after receiving 35 cycles for reasons other than disease progression or intolerability, or if patients attained a complete response and stopped treatment with pembrolizumab, they may be eligible for retreatment with pembrolizumab upon experiencing disease progression. pERC noted that in the trial, if pembrolizumab was withheld for toxicity, patients were able to resume pembrolizumab if appropriate and when toxicity had improved. pERC felt that</p>

Generic name (brand name)	Date of recommendation	Recommendation <sup>a</sup> and guidance on treatment sequencing
Pembrolizumab (Keytruda)	<a href="#">May 31, 2019</a>	<p>these criteria for retreatment with pembrolizumab following a progression-free time period and toxicity interruption were reasonable.</p> <p>pERC conditionally recommends the reimbursement of pembrolizumab (Keytruda) in combination with pemetrexed and platinum chemotherapy, for the treatment of metastatic non-squamous NSCLC, in adults with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC if the following conditions are met:</p> <ul style="list-style-type: none"> <li>• cost-effectiveness being improved to an acceptable level.</li> <li>• feasibility of adoption (budget impact) being addressed.</li> </ul> <p>Eligible patients include those with good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity to a maximum of 2 years, whichever comes first.</p> <p><b>Optimal sequencing guidance:</b></p> <ul style="list-style-type: none"> <li>• pERC noted that patients receiving pembrolizumab plus chemotherapy in the first-line setting would not receive subsequent PD-1 (e.g., nivolumab) or PD-L1 inhibitors (e.g., atezolizumab) in the second-line setting.</li> <li>• pERC noted that patients who are unable to tolerate pemetrexed would likely not be administered pembrolizumab. However, in this unlikely setting, it would be reasonable to continue single-agent pembrolizumab.</li> <li>• pERC considered the CGP’s expert opinion and agreed that for patients who received prior adjuvant or consolidation durvalumab and remain candidates for platinum-pemetrexed chemotherapy, it would be reasonable to consider treatment with platinum-pemetrexed plus pembrolizumab. In general, for such patients, it should be more than 12 months since they last received platinum-based therapy. For patients progressing during adjuvant or consolidation immune checkpoint inhibitor therapy there is limited data at this time to support further immune checkpoint inhibitor therapy.</li> <li>• pERC felt it is reasonable that patients who complete 2 years of pembrolizumab and discontinue therapy without progression, should have the option for retreatment with pembrolizumab if there is at least 6 months between completion of therapy and documented disease progression.</li> </ul>
Pembrolizumab (Keytruda)	<a href="#">January 3, 2020</a>	<p>pERC conditionally recommends the reimbursement of pembrolizumab in combination with carboplatin and paclitaxel for the treatment of patients with metastatic squamous NSCLC, in adults with no prior systemic chemotherapy treatment for metastatic NSCLC if the following conditions are met:</p> <ul style="list-style-type: none"> <li>• cost-effectiveness being improved to an acceptable level.</li> <li>• feasibility of adoption (budget impact) being addressed.</li> </ul> <p>Eligible patients include those with good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity to a maximum of 2 years, whichever comes first.</p> <p><b>Optimal sequencing guidance:</b></p> <ul style="list-style-type: none"> <li>• pERC noted that patients who receive pembrolizumab in the first-line setting would not be eligible to receive subsequent PD-1 (e.g., nivolumab) or PD-L1 (e.g., atezolizumab) inhibitors in the second-line setting.</li> </ul>

Generic name (brand name)	Date of recommendation	Recommendation <sup>a</sup> and guidance on treatment sequencing
		<ul style="list-style-type: none"> <li>• pERC acknowledged that for patients with PD-L1 TPS equal to or greater than 50%, pembrolizumab monotherapy represents the standard first-line therapy and that based on Keynote 407, pembrolizumab in combination with carboplatin and paclitaxel is an alternative first-line therapy. pERC supports having both options available to patients as these regimens have not been directly compared and an indirect comparison as part of this review shows no clear regimen that is superior in OS.</li> <li>• pERC noted that patients who completed 2 years of pembrolizumab and discontinue therapy without progression, should have an option of retreatment with pembrolizumab.</li> </ul>
Atezolizumab (Tecentriq)	<a href="#">June 20, 2018</a>	<p>pERC recommends reimbursement of atezolizumab (Tecentriq) for patients with locally advanced or metastatic NSCLC and who have disease progression on or after cytotoxic chemotherapy only if the following conditions are met:</p> <ul style="list-style-type: none"> <li>• cost-effectiveness being improved to an acceptable level and</li> <li>• the drug plan cost of treatment with atezolizumab should not exceed the public drug plan cost of treatment with the least costly alternative immunotherapy.</li> </ul> <p>Patients with genomic tumour driver aberrations (e.g., EGFR or ALK) should first be treated with targeted agents followed by cytotoxic chemotherapy prior to receiving atezolizumab. Treatment with atezolizumab should continue until confirmed disease progression or unacceptable toxicity.</p> <p><b>Optimal sequencing guidance:</b> pERC concluded that the optimal sequencing of atezolizumab and other treatments now available for the treatment of advanced or metastatic NSCLC is currently unknown. pERC was, therefore, unable to make an evidence-informed recommendation on sequencing following treatment with atezolizumab. pERC also noted that there is no direct evidence to inform the comparative efficacy of atezolizumab with PD-1 inhibitors (nivolumab and pembrolizumab). Thus, with their overlapping indications, there is no evidence to inform the choice of atezolizumab over the other available agents, or vice versa. There is also no evidence to support using PD-L1/PD-1 inhibitors in sequence (e.g., atezolizumab then nivolumab or pembrolizumab, or vice versa).</p>
Nivolumab (Opdivo)	<a href="#">June 3, 2016</a>	<p>pERC recommends funding nivolumab (Opdivo) conditional on the cost-effectiveness being improved to an acceptable level. Funding should be for the treatment of adult patients with advanced or metastatic NSCLC with disease progression on or after cytotoxic chemotherapy for advanced disease and have a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity.</p> <p><b>Optimal sequencing guidance:</b> pERC concluded that the optimal sequencing of nivolumab and other treatments now available for the treatment of advanced or metastatic NSCLC is currently unknown. pERC was, therefore, unable to make an evidence-informed recommendation on sequencing.</p>
Pembrolizumab (Keytruda)	<a href="#">November 3, 2016</a>	<p>pERC recommends reimbursement of pembrolizumab (Keytruda) conditional on the cost-effectiveness being improved to an acceptable level. Funding should be for the treatment of patients with metastatic NSCLC whose tumours express PD-L1 (as determined by a validated test) and who have disease progression on or</p>


Generic name (brand name)	Date of recommendation	Recommendation <sup>a</sup> and guidance on treatment sequencing
		<p>after cytotoxic chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on authorized therapy for these aberrations and cytotoxic chemotherapy prior to receiving pembrolizumab. Patients could receive up to 12 months of pembrolizumab if they experienced an investigator-determined confirmed radiographic disease progression, according to immune-related response criteria after stopping their initial treatment with pembrolizumab due to achievement of a confirmed complete response or having experienced 35 administrations of pembrolizumab. Funding should be for patients with a TPS of PD-L1 <math>\geq</math> 1% and who have good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity, or to a maximum of 2 years, whichever comes first.</p> <p><b>Optimal sequencing guidance:</b> pERC concluded that the optimal sequencing of pembrolizumab and other treatments now available for the treatment of advanced or metastatic NSCLC is currently unknown. pERC was, therefore, unable to make an evidence-informed recommendation on sequencing following pembrolizumab. pERC also noted that there is no direct evidence to inform the comparative efficacy of pembrolizumab with other PD-1 inhibitors. Thus, with their overlapping indications, there is no evidence to inform the choice of pembrolizumab over nivolumab, or vice versa. There is also no evidence to support using PD-1 inhibitors in sequence (e.g., pembrolizumab then nivolumab, or vice versa).</p>

ALK = anaplastic lymphoma kinase; CGP = Clinical Guidance Panel; CNS = central nervous system; EGFR = epidermal growth factor receptor; NSCLC = non-small cell lung cancer; PD-L1 = programmed death ligand 1; pERC = pCODR Expert Review Committee; PDC = platinum doublet chemotherapy; PD-L1 = programmed death-ligand 1; ROS1 = c-ros oncogene 1 receptor tyrosine kinase; TPS = Tumour Proportion Score.

<sup>a</sup> Summaries of the reimbursement conditions are provided; for the complete recommendations refer to the final recommendations posted on the CADTH website.

## Provisional Funding Algorithm

**Figure 1: Provisional Funding Algorithm Diagram for Non-Small Cell Lung Cancer Without Actionable Oncogenic Alterations**



<sup>a</sup> For patients who complete 2 years of therapy and discontinue without progression, retreatment is allowed.

<sup>b</sup> For patients who progress more than 6 months after completion of platinum doublet chemotherapy while on this regimen, retreatment with a histology-appropriate platinum doublet is allowed.

Note: Chemotherapy composition depends on histology (squamous versus non-squamous). Pemetrexed maintenance therapy may follow platinum-based chemotherapy if non-squamous histology.

Note: PD-L1 expression is determined using Tumour Proportion Score.

### Description of the Provisional Funding Algorithm

#### **Patients who completed prior PD-1 or PD-L1 inhibitor treatment less than 6 months ago**

In the first-line setting, platinum-based chemotherapy is used in patients with non-small cell lung cancer without actionable oncogenic alterations who completed prior PD-1 or PD-L1 inhibitor treatment less than 6 months ago. Docetaxel or pemetrexed are available second-line options upon progression.

#### **Patients who completed prior PD-1 or PD-L1 inhibitor treatment at least 6 months ago or with no prior PD-1 or PD-L1 inhibitor treatment**

Available treatment options for patients who completed prior PD-1 or PD-L1 inhibitor treatment at least 6 months ago or without prior PD-1 or PD-L1 inhibitor treatment depend on the tumour PD-L1 status of the patients, which is assessed using Tumour Proportion Score.

For patients with any PD-L1 status or whose PD-L1 status is unknown, available first-line treatment options include immunotherapy in combination with chemotherapy (either nivolumab/ipilimumab with 2 cycles of platinum doublet chemotherapy or pembrolizumab with platinum chemotherapy or pemetrexed) or platinum-based chemotherapy alone. Following progression on pembrolizumab plus chemotherapy or nivolumab plus ipilimumab with 2 cycles of chemotherapy, docetaxel or pemetrexed can be offered in second line. Among patients who have disease progression on or after first-line platinum-based chemotherapy, nivolumab or atezolizumab treatment can be considered in patients with any PD-L1 status or whose PD-L1 status is unknown, while pembrolizumab can be considered in patients whose tumours express PD-L1. For all patients, docetaxel or pemetrexed are available in subsequent lines of therapy.

In patients whose tumours express PD-L1 (tumour proportion score of 50% or greater), pembrolizumab monotherapy can be offered in the first-line setting. Cemiplimab monotherapy is currently under consideration for funding as another first-line treatment option. Available treatments in subsequent lines of therapy include platinum-based chemotherapy (as second-line) and docetaxel or pemetrexed (as third-line).